Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: Evaluation of the accutane SMART program

Archives of Dermatology

Volumn 141, Issue 5, 2005, Pages 563-569

  Brinker, Allen ^a,b   Kornegay, Cynthia ^a   Nourjah, Parivash ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN;

BIRTH CONTROL; COHORT ANALYSIS; FEMALE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; OBSERVATION; PHARMACY; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY TEST; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; RELIABILITY; REVIEW; RISK MANAGEMENT; VALIDATION PROCESS;

ABNORMALITIES, DRUG-INDUCED; CONTRACEPTION; DRUG LABELING; FEMALE; GUIDELINE ADHERENCE; HUMANS; ISOTRETINOIN; PATIENT COMPLIANCE; PHARMACIES; PREGNANCY; PREGNANCY TESTS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK MANAGEMENT; TERATOGENS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 18544383329     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.141.5.563     Document Type: Review

References (14)

1. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med. 1995;333:101-106.
2. Food and Drug Administration. Correspondence to Hoffmann-La Roche Inc re: NDA 18-662 and NDA 21-177), October 6, 2000. Available at: http://www.fda .gov/ohrms/dockets/ac/04/briefing/4017b1.htm. Accessed August 18, 2004.
3. Food and Drug Administration. Correspondence to Hoffmann-La Roche Inc. February 15, 2002. Available at: http://www.fda.gov/cder/foi/appletter/2002 /18562s046ltr.pdf. Accessed August 18, 2004.
4. Food and Drug Administration. Overview of Accutane S.M.A.R.T program, including approved product label, consents, and educational materials. Available at: http://www.fda.gov/cder/drug/infopage/accutane/smart.pdf. Accessed August 18, 2004.
5. Food and Drug Administration. FDA announces changes to the risk management program to prevent birth defects caused by Accutane. October 31, 2001. Available at: http://www.fda.gov/bbs/topics/ANSWERS/2001/ANS01113.html. Accessed August 18, 2004.
6. Food and Drug Administration. Review of prescription compliance survey to measure compliance with isotretinoin qualification stickers. February 2, 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/4017b1.htm. Accessed August 18, 2004.
7. Mitchell AA, Van Bennekom CM, Louik C. An assessment of the Accutane (isotretinoin) Pregnancy Prevention Program. Presented at: FDA Dermatologic Drugs Advisory Committee Meeting; September 18, 2000; Gaithersburg, Md. Slide presentation available at: http//:www.fda.gov/ohrms/dockets/ac/00/slides/3639s1i .ppt. Accessed August 18, 2004,
8. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol. 2000;136:1231-1236.
9. Hoffmann-La Roche. Submission-General Correspondence: 1-Year Report on the SMART Program. June 30, 2003.
10. IMS Health. IMS National Prescription Audit Plus: Accutane and generic isotretinoin, April 2001-March 2003. Data Extracted November 2003.
11. Mott DA, Pederson CA, Doucette WR, Gaither CA, Schommer JC. A national survey of U.S. pharmacists in 2000: assessing nonresponse bias of a survey methodology, AAPS PharmSci. 2001;3:E33.
12. Fowler FJ, Gallagher PM, Stringfellow VL, et al. Using telephone interviews to reduce nonresponse bias to mail surveys of health plan members. Med Care. 2002;40:190-200.
13. Brambilla DJ, McKinlay SM. A comparison of responses to mailed questionnaires and telephone interviews in a mixed mode health survey. Am J Epidemiol. 1987;126:962-971.
14. Food and Drug Administration. Review of prescription compliance survey materials and data with interest in compliance during the first year of the System to Manage Accutane Related Teratology (S.M.A.R.T)™ Program. February 2, 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/ 4017b1.htm. Accessed August 18, 2004.